Antiretroviral drug treatment interruption in human immunodeficiency virus–infected adults: Clinical and pathogenetic implications for the central nervous system

References

• Appleman M, Marshall D, Brey R, Houk R, Beatty D, Winn R, Melcher G, Wise M, Wumaya C, Boswell R (1988). Cerebrospinal fluid abnormalities in patients without AIDS who are seropositive for the human immunodeficiency virus. J Infect Dis 158: 193–199.
   Google Scholar
• Barbour JD, Wrin T, Grant RM, Martin JN, Segal MR, Petropoulos CJ, Deeks SG (2002). Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 76: 11104–11112.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM (2001). Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344: 472–480.
   PubMed Web of Science ®Google Scholar
• Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ (1999). Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 13: 1249–1253.
   PubMed Web of Science ®Google Scholar
• Dore GJ, Li Y, McDonald A, Ree H, Kaldor JM, Kaldo JM (2002). Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. J Acquir Immune Defic Syndr 29: 388–395.
   PubMed Web of Science ®Google Scholar
• Dybul M, Chun TW, Yoder C, Hidalgo B, Belson M, Hertogs K, Larder B, Dewar RL, Fox CH, Hallahan CW, Justement JS, Migueles SA, Metcalf JA, Davey RT, Daucher M, Pandya P, Baseler M, Ward DJ, Fauci AS (2001). Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci U S A 98: 15161–15166.
   PubMed Web of Science ®Google Scholar
• Hance AJ, Lemiale V, Izopet J, Lecossier D, Joly V, Massip P, Mammano F, Descamps D, Brun-Vezinet F, Clavel F (2001). Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 75: 6410–6417.
   PubMed Web of Science ®Google Scholar
• Havlir DV (2002). Structured intermittent treatment for HIV disease: necessary concession or premature compromise? Proc Natl Acad Sci U S A 99: 4–6.
   Google Scholar
• Huang W, Gamarnik A, Limoli K, Petropoulos CJ, Whitcomb JM (2003). Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J Virol 77: 1512–1523.
   Google Scholar
• Izopet J, Souyris C, Hance A, Sandres-Saune K, Alvarez M, Pasquier C, Clavel F, Puel J, Massip P (2002). Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J Infect Dis 185: 1506–1510.
   Google Scholar
• Liu NQ, Lossinsky AS, Popik W, Li X, Gujuluva C, Kriederman B, Roberts J, Pushkarsky T, Bukrinsky M, Witte M, Weinand M, Fiala M (2002). Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. J Virol 76: 6689–6700.
   PubMed Web of Science ®Google Scholar
• Lori F, Lisziewicz J (2001). Structured treatment interruptions for the management of HIV infection. JAMA 286: 2981–2987.
   PubMed Web of Science ®Google Scholar
• Oxenius A, Price DA, Gunthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, Garcia F, Hirschel B, McLean A, Phillips RE (2002). Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A 99: 13747–13752.
   PubMed Web of Science ®Google Scholar
• Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM (2000). A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44: 920–928.
   PubMed Web of Science ®Google Scholar
• Price RW, Paxinos EE, Grant RM, Drews B, Nilsson A, Hoh R, Hellmann NS, Petropoulos CJ, Deeks SG (2001). Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS 15: 1251–1259.
   PubMed Web of Science ®Google Scholar
• Price RW, Staprans S (1997). Measuring the “viral load” in cerebrospinal fluid in human immunodeficiency virus infection: window into brain infection? [editorial; comment]. Ann Neurol 42: 675–678.
   Google Scholar
• Price RW, Yiannoutsos C, Clifford D, Zaborski L, Tselis A, Sidtis J, Cohen B, Hall C, Erice A, Henry K (1999). Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS 13: 1677–1685.
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, Robbins GK, D’Aquila RT, Goulder PJ, Walker BD (2000). Immune control of HIV-1 after early treatment of acute infection. Nature 407: 523–526.
   PubMed Web of Science ®Google Scholar
• Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, McArthur JC (2001). HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology 56: 257–260.
   PubMed Web of Science ®Google Scholar
• Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, Aweeka F, Deeks S, Price RW (1999). Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS 13: 1051–1061.
   PubMed Web of Science ®Google Scholar
• Williams KC, Corey S, Westmoreland SV, Pauley D, Knight H, deBakker C, Alvarez X, Lackner AA (2001). Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J Exp Med 193: 905–915.
   PubMed Web of Science ®Google Scholar